Sector News

Medtronic appoints Madan Krishnan as VP Indian Sub-continent

September 8, 2016
Life sciences

Global medical technology major Medtronic plc has appointed Madan Krishnan as Vice President for Indian sub-continent.

In this role, Krishnan will lead the Medtronic Indian sub-continent business (ISC), which includes India, Sri Lanka, Bangladeshand Nepal, Medtronic plc said in a statement.

Commenting on the development, Medtronic AsiaPacific President Bob White said: “”We see tremendous growth potential in ISC and I have full confidence in Madan’s ability to be an engaged and collaborative industry leader while caring for our employees.”

Krishnan joined Medtronic in 2011. Prior to this appointment, Krishnan was vice president of finance, AsiaPacific (APAC).

Medtronic began its operations in Indiain 1979. Headquartered in Mumbai, the company has offices at Ahmedabad, Bengaluru, Chennai, Cochin, Dhaka, Gurgaon, Hyderabad, Kolkata, New Delhi, Puneand Vadodara.

Source: Business Standard

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach